Searchable abstracts of presentations at key conferences in endocrinology

ea0044p43 | Bone and Calcium | SFEBES2016

The influence of gender on the bone health of adolescent patients with hormonal deficiencies

Whittingham Pauline , Grounds Kerrie , Ahmad Aftab , Didi Mo , Corlett Pamela

Introduction: Previous audits demonstrated low bone mineral density (BMD) in adolescent patients with hormone deficiencies. We wanted to ascertain if gender had any relationship with the development of low BMD.Method: A retrospective analysis of 42 Transitional clinic patients who underwent DEXA scanning was made using case notes and hospital systems. Follow-up data was gathered as previous audit of 25 transitional patients had shown a significant number...

ea0044p76 | Clinical biochemistry | SFEBES2016

Time taken for GH-treated adolescent patients, transitioning to adult services, to reach IGF1 levels within the upper normal range: Do we need to monitor more frequently?

Grounds Kerrie , Whittingham Pauline , Didi Mo , Ahmad Aftab

Introduction: According to NICE: adults receiving growth hormone (GH) treatment, IGF1 levels should reach therapeutic range by 9 months. Patients are reviewed at 1, 3, 6, 9, 12 months and 6 months thereafter in our clinics. GH dose is titrated by 0.1 mg each visit. This work aims to compare the time it takes to get the IGF1 in range, between adults and adolescent patients attending our specialist regional clinics.Method: We performed a retrospective audi...

ea0034p12 | Bone | SFEBES2014

The influence of gender on the bone health of adolescent patients with hormonal deficiencies

Grounds Kerrie , Corlett Pamela , Ahmad Aftab , Whittingham Pauline

Introduction: Previous audits demonstrated low bone mineral density (BMD) in adolescent patients with hormone deficiencies. We wanted to ascertain if gender had any relationship with the development of low BMD.Method: A retrospective analysis of 42 transitional clinic patients who underwent DEXA scanning was made using case notes and hospital systems. Follow-up data was gathered as previous audit of 25 transitional patients had shown a significant number...

ea0034p193 | Nursing practise | SFEBES2014

Time taken for GH-treated adolescent patients, transitioning to adult services, to reach IGF1 levels within the upper normal range: do we need to monitor more frequently?

Grounds Kerrie , Didi Mohammed , Corlett Pamela , Whittingham Pauline , Ahmad Aftab

Introduction: According to NICE: adults receiving GH treatment, IGF1 levels should reach therapeutic range by 9 months. Patients are reviewed at 1, 3, 6, 9, 12 months and 6 months thereafter in our clinics. GH dose is titrated by 0.1 mg each visit. This work aims to compare the time it takes to get the IGF1 in range, between adults and adolescent patients attending our specialist regional clinics.Method: We performed a retrospective audit of 20 patients ...

ea0015p195 | Growth and development | SFEBES2008

Is vertical growth still possible at the age of 30?

Mon Aung , Saunders Simon , Whittingham Pauline , Vora Jiten

A 28-year-man originally from Africa presented with short stature. His height at first clinic visit was 128 cm and there was no family history of short stature. He had pale complexion, lack of facial/body hair and under-developed secondary sexual characteristics consistent with morphology of hypopituitaric dwarfism. Insulin stress test with adequate hypoglycaemia<2.2 mmol/l confirmed flat growth hormone (GH) response (peak <0.5 mU/l) and inadequate cortisol response (p...

ea0081p681 | Pituitary and Neuroendocrinology | ECE2022

The burden of adult growth hormone deficiency diagnostic tests: results of a patient experience survey in the UK

Lewis Harry , Mumford Joanne , McBride Pat , Whittingham Pauline , Darley Glenn , Chernai Nacima

Objectives: To collect qualitative and quantitative information on the burden of adult growth hormone deficiency (AGHD) diagnostic tests for the patient.Methods: A survey was published on The Pituitary Foundation’s website and social media pages; respondents completed it online using SmartSurvey over period of two months (October-November 2021). 105 respondents took the survey, with 9 screened out after the first question because they had never take...

ea0019p175 | Endocrine tumours and neoplasia | SFEBES2009

A patient with neurofibromatosis type-1 (NF1) presenting with multiple endocrine neoplasia (MEN)2B

Mon Aung , Malipatil Nagaraj , Sharma Dushyant , Aftab Rabia , Koay Yee , Whittingham Pauline , Hamilton Amanda , Vora Jiten

Background: NF1 and MEN2 are rare conditions known to associate with bilateral phaeochromochtomas. We describe, with relevant associated radiology, a NF1 patient developing a series of neuroendocrine tumours including bilateral phaeochromocytomas.Clinical case: A 39-year-old lady presented with long standing episodic abdominal pain, diarrhoea, palpitation and sweating. Past history includes first arch syndrome and NF1 at teens and total thyroidectomy for...

ea0013p111 | Clinical practice/governance and case reports | SFEBES2007

Acute presentation of pituitary stalk tumor

Nagareddy VR , Thomas CM , Joshi Ashwin , Wong Stephen , Vora JP , Varma TRK , Whittingham Pauline , Corlett Pamela

An 18 year old lady was seen in endocrine clinic in October 2004 with 10 month history of polyuria, polydypsia and lethargy. Previous medical history includes Graves thyrotoxicosis which is treated with carbimazole.Clinical examination was unremarkable.Investigations and management: Urine osmolality −84 mosmol (250–750), serum osmolality −290 mosmol (288–298), full blood count, fasting glucose, renal, liver fu...

ea0086p98 | Neuroendocrinology and Pituitary | SFEBES2022

The pituitary patients’ experiences pre and during the Covid-19 pandemic

McBride Pat , Brooke Antonia , Charlick James , Newell-Price John , Swindells Pauline , Wass John , Whittingham Pauline , Renwick Ren

Background: Patient experience is a crucial part of patient care, but is not systematically assessed. In light of this we performed a UK-wide survey to understand the care experiences of patients with pituitary conditions over the preceding three years.Methods: In collaboration with patients and pituitary experts a web-based survey was designed, aimed at patients 18yrs and over. Specific topics included: assessment of information provision, communication...

ea0013p3 | Bone | SFEBES2007

Differences in parathyroid hormone secretory rhythm and sensitivity in aging women with osteoporosis and declining insulin like growth factor-1 concentration, compared to young healthy premenopausal women

Joseph Franklin , Ahmad Aftab M , Joshi Ashwin , Wakil Amar , Durham Brian H , Whittingham Pauline , Fraser William D , Vora Jiten P

Introduction: Adult growth hormone deficiency (AGHD) is associated with target organ insensitivity to parathyroid hormone (PTH) and abnormal PTH circadian rhythm. In aging women with established osteoporosis, GH and insulin like growth factor -1 (IGF-1) concentrations are low and administration of GH has been shown to increase bone turnover and bone mineral density (BMD), but the mechanisms remain unclear. Consequently we investigated the effects of declining GH and IGF-1 conc...